Drug Development in Contemporary Oncology
2008
Histone Deacetylase Inhibitors as Novel Anticancer Therapeutics
publication
Evidence: moderate
Author Information
Author(s): Walkinshaw D.R., Yang X.J.
Primary Institution: Rosalind and Morris Goodman Cancer Centre, McGill University
Hypothesis
Altered histone deacetylase activity may play a causative role in tumorigenesis and metastasis.
Conclusion
Histone deacetylase inhibitors show promise as effective treatments for various cancers.
Supporting Evidence
- Histone deacetylase inhibitors have been shown to selectively kill cancer cells.
- Several histone deacetylase inhibitors are currently in phase II and III clinical trials.
- One histone deacetylase inhibitor, Zolinza, has been approved for treating cutaneous T-cell lymphoma.
Takeaway
Scientists are studying special drugs that can help fight cancer by changing how genes work in cancer cells.
Methodology
This mini-review provides an overview of histone deacetylase inhibitors and their effects in clinical trials.
Limitations
The review does not provide specific data on clinical trial outcomes or detailed statistical analyses.
Want to read the original?
Access the complete publication on the publisher's website